Back

Ticagrelor versus clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome: a post-hoc analysis of the ALPHEUS study

26 August 2023 (10:42 - 10:51)
Organised by: Logo
Congress Presentation Part of: Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Benoit Lattuca

Nimes Caremeau University Hospital Centre, Nimes (France)

4 More presentations in this session

Presentation thumbnail
Ticagrelor or Clopidogrel to reduce ischemic events after Percutaneous Coronary Intervention in chronic coronary syndrome in clopidogrel naive patient: the ALPHEUS Naive sub-study.
Professor J. Silvain (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: A systematic review and meta-analysis
Miss R. Markides (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Clopidogrel vs. aspirin in the chronic maintenance period following percutaneous coronary intervention in high thrombotic and high bleeding risk patients:sub-analysis of the HOST-EXAM Extended study
Doctor J. Chung (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention
Doctor F. Gerardo (Amadora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 10:42 CET
You may be interested in
thumbnail
Congress Session
Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease
thumbnail
Congress Presentation
Complex versus non-complex, should we adjust the antiplatelet strategy to the type of percutaneous coronary intervention? Results from a real world PCI population
thumbnail
Congress Presentation
Ticagrelor or Clopidogrel to reduce ischemic events after Percutaneous Coronary Intervention in chronic coronary syndrome in clopidogrel naive patient: the ALPHEUS Naive sub-study.

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources